Research Paper Volume 10, Issue 12 pp 4000—4023

The ER-alpha mutation Y537S confers Tamoxifen-resistance via enhanced mitochondrial metabolism, glycolysis and Rho-GDI/PTEN signaling: Implicating TIGAR in somatic resistance to endocrine therapy

Figure 10. Schematic diagram summarizing the role of the ESR1-Y537S mutation in driving Tamoxifen-resistance. Note that the Y537S mutation induces metabolic reprogramming, with the hyper-activation of both mitochondrial and glycolytic energetic pathways.